- Home
- BCDA
BCDA
BioCardia Inc.
as 11-15-2024 4:00pm EST
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SUNNYVALE |
| Market Cap: | 7.9M | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 61.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.84 - $12.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | $71,000 | Revenue Growth: | -87.54% |
| Revenue Growth (this year): | 6.92% | Revenue Growth (next year): | N/A |
Latest BioCardia Inc. News
BCDA Breaking Stock News: Dive into BCDA Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)
GuruFocus.com
4 days ago
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...
GlobeNewswire
5 days ago
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
GlobeNewswire
12 days ago
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
GlobeNewswire
21 days ago
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
GuruFocus.com
a month ago
BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
MT Newswires
2 months ago
BioCardia Regains Compliance with Nasdaq Listing Rules for Minimum Equity Levels
GlobeNewswire
2 months ago
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
Compare BCDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCDA BioCardia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.